论文部分内容阅读
药理学状况用胃蛋白酶或纤维蛋白溶酶裂解 Ig 分子,所得到的静脉注射免疫球蛋白(IVIG),属于现在已不用的第一代产品;用β-丙内酯、磺基化、还原或烷基化等化学改性法所得到的第二代产品,或多或少地损害了 Fc 相关的功能。目前,这些制品都将被具有完整识别和效应功能的IgG 分子的第三代产品所取代。第三代产品的制备方法包括 pH4时痕量胃蛋白酶法或 PEG法,或用离子交换剂批量吸附处理法等。这类
Pharmacological status Ig molecules are cleaved with pepsin or plasmin, and the resulting IVIG is a first-generation product that has not been used up to now; with beta-propiolactone, sulfonated, reduced or Second-generation products obtained by chemical modifications such as alkylation impair more or less Fc-related functions. At present, these products will be replaced by the third generation of IgG molecules with complete recognition and effector functions. The third generation of product preparation methods include pH4 trace pepsin or PEG method, or with ion exchange batch adsorption treatment method. This class